ME00782B - Postupak za radioobilježavanje antitijela i postupak za određivanje imunoreaktivnosti radioobilježenih antitijela, ćelijskim vezivanjem - Google Patents

Postupak za radioobilježavanje antitijela i postupak za određivanje imunoreaktivnosti radioobilježenih antitijela, ćelijskim vezivanjem

Info

Publication number
ME00782B
ME00782B MEP-2009-21A MEP2109A ME00782B ME 00782 B ME00782 B ME 00782B ME P2109 A MEP2109 A ME P2109A ME 00782 B ME00782 B ME 00782B
Authority
ME
Montenegro
Prior art keywords
radiolabeling
cell
antibodies
lmmunoreactivity
evaluating
Prior art date
Application number
MEP-2009-21A
Other languages
English (en)
French (fr)
Inventor
Paul Chinn
Ronald Morena
Michael Labarre
John E Leonard
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of ME00782B publication Critical patent/ME00782B/me

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Packages (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Otkriveni su kitovi za radioobeležavanje antitela i ćelijsko-vezivanje za radioobeležavanje i testiranje terapeutskih antitela u kliničkom okruženju. Kitovi su posebno dizajnirani za pravljenje i odre đ ivanje imunoreaktivnosti radioobeleženih antitela kao što su anti-CD20 konju-gati koja su pogodna za upotrebu za tretman i oslikavanje tumora limfoma B ćelija. Svi reagensi kita su sterilni i dizajnirani su da dostignu visok nivo radioobeležavanja antitela i stabilnost produkta sa rezultatima koji su visoko reproducibilni.
MEP-2009-21A 1999-03-01 2000-02-29 Postupak za radioobilježavanje antitijela i postupak za određivanje imunoreaktivnosti radioobilježenih antitijela, ćelijskim vezivanjem ME00782B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/259,337 US20020102208A1 (en) 1999-03-01 1999-03-01 Radiolabeling kit and binding assay
PCT/US2000/005061 WO2000052473A2 (en) 1999-03-01 2000-02-29 Radiolabeling kit and binding assay

Publications (1)

Publication Number Publication Date
ME00782B true ME00782B (me) 2012-03-20

Family

ID=22984524

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-21A ME00782B (me) 1999-03-01 2000-02-29 Postupak za radioobilježavanje antitijela i postupak za određivanje imunoreaktivnosti radioobilježenih antitijela, ćelijskim vezivanjem

Country Status (35)

Country Link
US (2) US20020102208A1 (me)
EP (2) EP1192463B1 (me)
JP (1) JP4704570B2 (me)
KR (1) KR100729247B1 (me)
CN (1) CN1235639C (me)
AT (1) ATE433108T1 (me)
AU (1) AU776747B2 (me)
BG (1) BG65690B1 (me)
BR (2) BRPI0008719B8 (me)
CA (2) CA2362119C (me)
CY (2) CY1109335T1 (me)
CZ (2) CZ303262B6 (me)
DE (1) DE60042326D1 (me)
DK (2) DK1192463T3 (me)
EE (1) EE05650B1 (me)
ES (2) ES2526723T3 (me)
HK (2) HK1045730B (me)
HR (1) HRP20010714B1 (me)
HU (2) HU229627B1 (me)
IL (1) IL145109A0 (me)
ME (1) ME00782B (me)
MX (1) MXPA01008837A (me)
MY (1) MY138674A (me)
NO (2) NO329142B1 (me)
NZ (2) NZ530868A (me)
PL (1) PL205780B1 (me)
PT (2) PT1192463E (me)
RS (1) RS51778B (me)
RU (1) RU2251110C2 (me)
SI (2) SI1192463T1 (me)
SK (2) SK287745B6 (me)
TW (1) TWI294969B (me)
UA (1) UA78484C2 (me)
WO (1) WO2000052473A2 (me)
ZA (1) ZA200106943B (me)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US6207858B1 (en) * 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives
EP1918305A1 (en) 1999-08-11 2008-05-07 Biogen Idec Inc. New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
EP1717251B1 (en) 2000-10-02 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Therapy for B-cell malignancies using human anti-CD40 antibodies
AU2002307037B2 (en) * 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
WO2003024388A2 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
EP1581794B1 (en) 2003-01-10 2008-09-17 Millennium Pharmaceuticals, Inc. Method of determining risk for prostate cancer recurrence
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7591953B2 (en) * 2003-06-25 2009-09-22 Peregrine Pharmaceuticals, Inc. Methods and apparatus for continuous large-scale radiolabeling of proteins
JP4810431B2 (ja) 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｂ細胞に関連する癌に対する治療方法
DE602004028272D1 (de) 2003-11-04 2010-09-02 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-monoklonalen antikörpern zur behandlung von multiplem myelom
CA2544852A1 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
DK1682178T3 (da) 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Fremgangsmåder til terapi af cancere der udtrykker CD-40-antigenet
DE602004028270D1 (de) 2003-11-04 2010-09-02 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
US8333970B2 (en) 2005-05-18 2012-12-18 Novartis Ag Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease
KR101245462B1 (ko) 2005-07-08 2013-03-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｓｐ35 항체 및 그의 용도
WO2007023408A2 (en) * 2005-08-25 2007-03-01 Koninklijke Philips Electronics N.V. 4d image-based planning methods and apparatus for targeted therapy
ES2548518T3 (es) * 2005-11-23 2015-10-19 Ventana Medical Systems, Inc. Conjugado molecular
GEP20125628B (en) 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
DK2037967T3 (en) 2006-06-16 2017-03-13 Univ Pennsylvania PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US20100130449A1 (en) * 2006-11-10 2010-05-27 Alphaptose Gmbh Use of Tri-Substituted Glycerol Compounds for the Treatment of Radiation Injuries
CZ300074B6 (cs) * 2006-12-20 2009-01-21 Azacycles S. R. O. Inteligentní trífunkcní makrokonjugáty a farmaceutický nebo diagnostický prostredek s jejich obsahem
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CN101636168B (zh) 2007-01-09 2013-05-29 比奥根艾迪克Ma公司 Sp35抗体及其用途
PT2234600E (pt) * 2007-12-21 2014-09-25 Hoffmann La Roche Formulação de anticorpos
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
CA2730620A1 (en) 2008-07-16 2010-01-21 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
MX338067B (es) 2008-07-16 2016-04-01 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
JP2011528902A (ja) 2008-07-25 2011-12-01 インスティテュート・フォー・リサーチ・イン・バイオメディシン 抗ａ型インフルエンザウイルス中和抗体およびその使用
AU2009305113B2 (en) 2008-10-13 2015-07-16 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
US20110212106A1 (en) 2010-01-20 2011-09-01 Institute For Research In Bioscience Hiv-1 neutralizing antibodies and uses thereof
SI3117709T1 (sl) 2010-03-12 2018-12-31 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
WO2012019128A1 (en) 2010-08-06 2012-02-09 Genzyme Corporation Vegf antagonist compositions and uses thereof
CN103237902A (zh) * 2010-08-13 2013-08-07 Rdm企业股份有限公司 减少糖的颜色的方法和组合物
SI3045183T1 (sl) 2011-03-11 2018-11-30 Genzyme Corporation Pegiliran Apelin in njegove uporabe
SI2734545T1 (sl) 2011-07-18 2019-06-28 Institute For Research In Biomedicine Protitelesa, ki nevtralizirajo virus influence A in njihova uporaba
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
CA2865856C (en) 2012-03-20 2023-03-14 Humabs Biomed Sa Antibodies that neutralize rsv, mpv and pvm and uses thereof
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
RU2522203C2 (ru) * 2012-06-26 2014-07-10 Василий Александрович Ишутин Способ контроля стерилизации материалов и изделий
WO2014009426A2 (en) * 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
IL275376B2 (en) 2013-03-11 2024-01-01 Genzyme Corp Polypeptides with hyperglycosidic bonds
WO2014165216A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
WO2014202775A1 (en) 2013-06-21 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
RU2558929C2 (ru) * 2013-08-08 2015-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" (НИИ Кардиологии) СПОСОБ ОПРЕДЕЛЕНИЯ СВЯЗЫВАНИЯ РАДИОФАРМПРЕПАРАТА НА ОСНОВЕ ЦИПРОФЛОКСАЦИНА, МЕЧЕННОГО 99mTc C БАКТЕРИЯМИ
CN112142845A (zh) 2013-08-13 2020-12-29 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
US11052177B2 (en) 2013-09-06 2021-07-06 The Trustees Of The University Of Pennsylvania Antimicrobial polymer layers
AU2014329609B2 (en) 2013-10-02 2019-09-12 Humabs Biomed Sa Neutralizing anti-influenza A antibodies and uses thereof
CA2940823C (en) 2014-02-27 2017-03-28 Board Of Regents, The University Of Texas System Methods and compositions for isolating exosomes
US10995148B2 (en) 2014-03-19 2021-05-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
ES2915101T3 (es) 2014-03-27 2022-06-20 Bird Rock Bio Inc Anticuerpos que se unen al receptor cannabinoide 1 (CB1) humano
AU2015289805B2 (en) 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
WO2016055950A1 (en) 2014-10-08 2016-04-14 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
WO2016057769A2 (en) 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
CN114805558B (zh) 2014-11-18 2023-12-29 胡默波斯生物医学公司 强力地中和狂犬病毒和其它狂犬病毒属病毒的抗体和其用途
DK3303384T3 (da) 2015-06-01 2021-10-18 Medimmune Llc Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf
EP3328500B1 (en) 2015-07-30 2023-04-12 The Trustees of the University of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 antagonists
WO2017040708A1 (en) 2015-08-31 2017-03-09 Fruition Marketing, Llc Consumer usable device with redeemable member
US10633445B2 (en) 2015-09-15 2020-04-28 Board Of Regents The University Of Texas System T-cell receptor (TCR)-binding antibodies and uses thereof
MA43049A (fr) 2015-09-30 2018-08-08 Bird Rock Bio Inc Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
SG11201805001UA (en) 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
WO2018010789A1 (en) * 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
US20200093909A1 (en) 2017-04-19 2020-03-26 Institute For Research In Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
SG11201909466RA (en) 2017-05-05 2019-11-28 Vaccinex Inc Human anti-semaphorin 4d antibody
CA3069703A1 (en) 2017-07-19 2019-01-24 Steven Hoffman Compositions for treating stress-related disorders
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
RU2700584C1 (ru) * 2018-12-13 2019-09-18 Общество С Ограниченной Ответственностью "Апто-Фарм" Способ оценки сродства олигонуклеотида
PT3898668T (pt) 2018-12-19 2023-12-06 Humabs Biomed Sa Anticorpos que neutralizam o vírus da hepatite b e suas utilizações
CA3152511A1 (en) 2019-08-29 2021-03-04 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
BR112022016999A2 (pt) 2020-02-28 2022-10-25 Genzyme Corp Polipeptídeos de ligação modificados para conjugação de fármacos otimizada
CA3181985A1 (en) 2020-06-11 2021-12-16 Simone DIGIOVANNI Use of cxcl13 binding molecules to promote peripheral nerve regeneration
US20240092872A1 (en) 2021-01-26 2024-03-21 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
WO2024068944A1 (en) 2022-09-30 2024-04-04 Sanofi Anti-cd28 antibodies
US20240166750A1 (en) 2022-10-25 2024-05-23 Ablynx N.V. GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994966A (en) * 1972-09-28 1976-11-30 The Board Of Trustees Of The Leland Stanford Junior University Chelating agents
US4043998A (en) * 1974-10-09 1977-08-23 The Board Of Trustees Of The Leland Stanford Junior University 1-(P-benzenediazonium)-ethylenediamine tetraacetic acid
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460559A (en) * 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
JPS5982222U (ja) * 1982-11-26 1984-06-02 松井　三郎 眼鏡
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4707352A (en) 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4636380A (en) 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4824986A (en) * 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) * 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4926869A (en) * 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
AU593611B2 (en) * 1986-02-14 1990-02-15 Nihon Medi-Physics Co., Ltd. High molecular compounds having amino groups, and their utilization
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
EP0484989B1 (en) * 1986-09-05 1996-04-24 GANSOW, Otto A. Polysubstituted diethylenetriamine chelates for forming a metal-chelate-protein conjugate
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) * 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5217704A (en) 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
AU619218B2 (en) 1987-11-06 1992-01-23 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
WO1989011475A1 (en) * 1988-05-25 1989-11-30 The United States Of America, As Represented By Th Macrocyclic chelates and methods of use thereof
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5376356A (en) * 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
US5162115A (en) * 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5009069A (en) * 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
EP0556285A4 (en) 1990-11-05 1993-10-27 Bristol-Myers Squibb Company Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
US5208008A (en) * 1990-11-14 1993-05-04 University Of Pittsburgh Regioselective chemical modification of monoclonal antibodies
CA2075928A1 (en) * 1991-01-11 1992-07-12 Roger W. Hackett Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material
US5403573A (en) * 1992-04-23 1995-04-04 The Curators Of The University Of Missouri Radiolabeled protein composition and method for radiation synovectomy
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
EP0752248B1 (en) * 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5728369A (en) 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5942210A (en) 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay

Also Published As

Publication number Publication date
SI1192463T1 (sl) 2009-10-31
EP2112512A3 (en) 2009-12-16
NZ513788A (en) 2004-03-26
IL145109A0 (en) 2002-06-30
CY1109335T1 (el) 2014-07-02
BRPI0017596B8 (pt) 2023-04-25
PT2112512E (pt) 2015-01-13
BRPI0017596A2 (pt) 2011-09-27
WO2000052473A2 (en) 2000-09-08
RS51778B (sr) 2011-12-31
KR20020021772A (ko) 2002-03-22
SK288096B6 (sk) 2013-07-02
CA2362119A1 (en) 2000-09-08
SK12162001A3 (sk) 2002-12-03
HU230516B1 (hu) 2016-10-28
EP2112512A2 (en) 2009-10-28
EE05650B1 (et) 2013-04-15
ES2328100T3 (es) 2009-11-10
BRPI0008719A (pt) 2001-12-26
WO2000052473A9 (en) 2001-03-08
WO2000052473A3 (en) 2002-01-31
RU2251110C2 (ru) 2005-04-27
CA2742153A1 (en) 2000-09-08
DK2112512T3 (en) 2014-12-15
CN1345417A (zh) 2002-04-17
DE60042326D1 (de) 2009-07-16
EP1192463A2 (en) 2002-04-03
YU61601A (sh) 2004-07-15
EP1192463B1 (en) 2009-06-03
JP2002538179A (ja) 2002-11-12
DK1192463T3 (da) 2009-10-05
ATE433108T1 (de) 2009-06-15
BG105957A (en) 2002-08-30
BRPI0008719B8 (pt) 2021-07-06
TWI294969B (me) 2008-03-21
CN1235639C (zh) 2006-01-11
HU229627B1 (en) 2014-03-28
UA78484C2 (en) 2007-04-10
NZ530868A (en) 2005-12-23
HK1045730A1 (en) 2002-12-06
SI2112512T1 (sl) 2015-02-27
BRPI0008719B1 (pt) 2015-07-21
PL205780B1 (pl) 2010-05-31
BRPI0017596B1 (pt) 2015-09-01
CA2362119C (en) 2012-12-11
HK1131208A1 (en) 2010-01-15
PT1192463E (pt) 2009-09-10
CA2742153C (en) 2015-04-14
NO329142B1 (no) 2010-08-30
US20020102208A1 (en) 2002-08-01
CZ306959B6 (cs) 2017-10-11
MXPA01008837A (es) 2002-05-14
HRP20010714A2 (en) 2003-02-28
NO20100717L (no) 2001-10-31
US20050169838A1 (en) 2005-08-04
AU3505200A (en) 2000-09-21
HUP0202522A2 (hu) 2002-11-28
CZ303262B6 (cs) 2012-07-04
NO20014245D0 (no) 2001-08-31
CY1116265T1 (el) 2017-02-08
CZ20013126A3 (cs) 2002-07-17
AU776747B2 (en) 2004-09-23
ES2526723T3 (es) 2015-01-14
KR100729247B1 (ko) 2007-06-15
JP4704570B2 (ja) 2011-06-15
HUP1300275A2 (en) 2002-11-28
NO20014245L (no) 2001-10-31
HK1045730B (zh) 2006-08-18
ZA200106943B (en) 2002-11-22
PL352531A1 (en) 2003-08-25
MY138674A (en) 2009-07-31
EP2112512B1 (en) 2014-11-19
BG65690B1 (bg) 2009-06-30
NO330705B1 (no) 2011-06-20
HRP20010714B1 (en) 2009-01-31
US7608241B2 (en) 2009-10-27
SK287745B6 (sk) 2011-08-04
EE200100465A (et) 2002-10-15
HUP0202522A3 (en) 2011-03-28

Similar Documents

Publication Publication Date Title
ME00782B (me) Postupak za radioobilježavanje antitijela i postupak za određivanje imunoreaktivnosti radioobilježenih antitijela, ćelijskim vezivanjem
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
BRPI9912227B1 (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
NO20005694L (no) Spesifikke bindingsmolekyler for scintigrafi, konjugater som inneholder disse og terapeutiske fremgangsmåter for behandling av angiogenese
BR0012069A (pt) Composições e métodos para a terapia e diagnóstico de câncer pulmonar
BR9912007A (pt) Composições e métodos para terapia e diagnóstico de câncer de próstata
IL142647A0 (en) A method and kit for measuring proteasome activity
DK1021534T3 (da) Hepatitis C-receptorprotein CD81
DE60014064D1 (de) Einetenascin-c isoform als marker für neoplasmen
AR029540A1 (es) COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
IT1231476B (it) Metodo radioimmunologico per la determinazione quantitativa del dietilstilbestrolo e dello zeranolo nei sieri e nelle urine di animali da allevamento e relativo kit
MX9800821A (es) Aislamiento y/o conservacion de celulas dentriticas para la inmunoterapia del cancer de la prostata.